RS83503A - Pharmaceutical dosage form of amorphous nelfinavir mesylate - Google Patents

Pharmaceutical dosage form of amorphous nelfinavir mesylate

Info

Publication number
RS83503A
RS83503A YU83503A YUP83503A RS83503A RS 83503 A RS83503 A RS 83503A YU 83503 A YU83503 A YU 83503A YU P83503 A YUP83503 A YU P83503A RS 83503 A RS83503 A RS 83503A
Authority
RS
Serbia
Prior art keywords
dosage form
nelfinavir mesylate
pharmaceutical dosage
amorphous nelfinavir
amorphous
Prior art date
Application number
YU83503A
Other languages
English (en)
Inventor
Martin Howard Infeld
Wantanee Phuapradit
Navnit Hargovindas Shah
Lin Zhang
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of RS83503A publication Critical patent/RS83503A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Čvrst pojedinačni oralni farmaceutski oblik doze amorfnog nelfinavir mezilata je obezbeđen, koji sadrži amorfni nelfinavir mezilat, i farmaceutski prihvatljiv, u vodi rastvoran, ne-jonski sintetički blok kopolimer etilen oksida i propilen oksida, gde pomenuti kopolimer ima temperaturu topljenja od najmanje 40øC. Postupak granulacije vrele istopine za dobijanje oblika doze je obezbeđen.
YU83503A 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate RS83503A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (1)

Publication Number Publication Date
RS83503A true RS83503A (en) 2006-10-27

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
YU83503A RS83503A (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Country Status (37)

Country Link
US (1) US7014866B2 (sr)
EP (1) EP1390063B1 (sr)
JP (1) JP4101661B2 (sr)
KR (1) KR100554816B1 (sr)
CN (1) CN1255185C (sr)
AR (1) AR034320A1 (sr)
AT (1) ATE282428T1 (sr)
BG (1) BG108311A (sr)
BR (1) BR0209325A (sr)
CA (1) CA2444116C (sr)
CZ (1) CZ20033211A3 (sr)
DE (1) DE60201988T2 (sr)
EA (1) EA006627B1 (sr)
EC (1) ECSP034827A (sr)
ES (1) ES2231717T3 (sr)
GE (1) GEP20053466B (sr)
GT (1) GT200200079A (sr)
HK (1) HK1070285A1 (sr)
HR (1) HRP20030873B1 (sr)
HU (1) HU229938B1 (sr)
IL (2) IL158306A0 (sr)
IS (1) IS7010A (sr)
JO (1) JO2401B1 (sr)
MA (1) MA27018A1 (sr)
MX (1) MXPA03009971A (sr)
MY (1) MY128509A (sr)
NO (1) NO20034689D0 (sr)
NZ (1) NZ528689A (sr)
PA (1) PA8544501A1 (sr)
PE (1) PE20021159A1 (sr)
PL (1) PL366998A1 (sr)
PT (1) PT1390063E (sr)
RS (1) RS83503A (sr)
SK (1) SK14572003A3 (sr)
TW (1) TWI234461B (sr)
UA (1) UA76463C2 (sr)
WO (1) WO2002089835A2 (sr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767429B2 (ja) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
JP4731320B2 (ja) * 2003-07-15 2011-07-20 アリジェン製薬株式会社 抗コロナウイルス剤
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005065657A2 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
EP1904067B2 (en) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
DK1928427T3 (da) * 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
PL1962808T3 (pl) * 2005-12-14 2011-03-31 Hoffmann La Roche Preparat proleku przeciw HCV
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
CA2660086C (en) * 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008131259A1 (en) * 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US20090042842A1 (en) 2007-04-25 2009-02-12 Concert Pharmaceuticals, Inc. Analogues of cilostazol
CA2630084A1 (en) * 2007-04-30 2008-10-30 Mark Andreychuk Coiled tubing with retainer for conduit
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
EP3632916B1 (en) 2007-05-01 2022-06-08 Concert Pharmaceuticals Inc. Morphinan compounds
EP3825306B8 (en) 2007-05-01 2023-08-02 Sun Pharmaceutical Industries, Inc. Morphinan compounds
PL2345653T3 (pl) 2007-05-01 2013-05-31 Concert Pharmaceuticals Inc Związki morfianu
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
BRPI0816513A2 (pt) * 2007-10-19 2015-03-24 Purdue Research Foundation Composição farmacêutica e método para preparar a suspensão sólida
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
US20090239886A1 (en) 2008-02-29 2009-09-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
SI2334678T1 (sl) 2008-09-19 2013-05-31 Concert Pharmaceuticals Inc. Spojine morfinana
EP2364151A1 (en) 2008-10-30 2011-09-14 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
EP3090760A1 (en) 2008-10-30 2016-11-09 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
US9096646B2 (en) 2008-11-04 2015-08-04 Anchor Therapeutics, Inc. CXCR4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
AP2909A (en) 2009-03-17 2014-05-31 Concert Pharmaceuticals Inc Pyrazinoisoquinoline Compounds
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
JP2012531419A (ja) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
WO2011109464A1 (en) 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
PT2579860E (pt) 2010-06-14 2014-05-30 Ratiopharm Gmbh Composição farmacêutica que contém ivabradina com libertação modificada
WO2012037060A1 (en) 2010-09-13 2012-03-22 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
EP2678337A1 (en) 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
RS59744B1 (sr) 2011-05-18 2020-02-28 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
AU2013208109A1 (en) 2012-01-09 2014-08-14 Anchor Therapeutics, Inc. APJ receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
US10017445B2 (en) 2012-07-12 2018-07-10 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP2885303B1 (en) 2012-08-17 2018-12-26 CoNCERT Pharmaceuticals, Inc. Deuterated baricitinib
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
US20150299166A1 (en) 2012-12-20 2015-10-22 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
WO2014100733A1 (en) 2012-12-21 2014-06-26 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA201892726A1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
BR112016028119A2 (pt) 2014-06-06 2017-08-22 Res Triangle Inst Agonistas receptores de apelina (apj) e usos dos mesmos
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
US10301281B2 (en) 2014-12-11 2019-05-28 Merck Sharp & Dohme Corp. Crystal forms of a CCR5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
CA2981495C (en) 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
MX2018003331A (es) 2015-09-21 2018-08-16 Vertex Pharmaceuticals Europe Ltd Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
EP3386976A1 (en) 2015-12-09 2018-10-17 Research Triangle Institute, International Improved apelin receptor (apj) agonists and uses thereof
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
KR20190003711A (ko) 2016-05-04 2019-01-09 콘서트 파마슈티컬즈, 인크. 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
JP7061079B2 (ja) 2016-07-04 2022-04-27 アヴェニール ファーマシューティカルズ， インコーポレイテッド 重水素化デキストロメトルファンの合成方法
US11596605B2 (en) 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
CA3036382A1 (en) 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
BR112019024177A2 (pt) 2017-05-19 2020-06-02 Superb Wisdom Limited Derivados de resiquimode
JP7518765B2 (ja) 2017-11-22 2024-07-18 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
MX2023005027A (es) 2020-10-28 2023-07-31 Sun Pharmaceutical Ind Inc Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
JP2024532765A (ja) 2021-08-12 2024-09-10 サン ファーマシューティカル インダストリーズ，インコーポレイテッド Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JP4083818B2 (ja) * 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
JP2002522354A (ja) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ，インコーポレイテッド 固溶体ビードレット
JP4815085B2 (ja) * 1999-11-12 2011-11-16 アボット・ラボラトリーズ 固体分散体医薬製剤
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
CZ20033211A3 (cs) 2004-09-15
MXPA03009971A (es) 2004-02-12
HK1070285A1 (en) 2005-06-17
ATE282428T1 (de) 2004-12-15
IL158306A (en) 2008-11-03
AR034320A1 (es) 2004-02-18
CA2444116C (en) 2009-01-20
ECSP034827A (es) 2003-12-24
US20030021840A1 (en) 2003-01-30
IL158306A0 (en) 2004-05-12
EP1390063A2 (en) 2004-02-25
NZ528689A (en) 2005-03-24
HUP0401238A3 (en) 2012-09-28
CN1255185C (zh) 2006-05-10
HRP20030873B1 (en) 2006-04-30
MY128509A (en) 2007-02-28
HUP0401238A2 (hu) 2004-12-28
US7014866B2 (en) 2006-03-21
ES2231717T3 (es) 2005-05-16
PL366998A1 (en) 2005-02-07
GT200200079A (es) 2002-12-05
IS7010A (is) 2003-10-30
KR100554816B1 (ko) 2006-02-22
NO20034689L (no) 2003-10-20
PA8544501A1 (es) 2002-11-18
MA27018A1 (fr) 2004-12-20
WO2002089835A3 (en) 2003-05-01
BR0209325A (pt) 2004-07-20
PT1390063E (pt) 2005-03-31
SK14572003A3 (sk) 2004-12-01
EP1390063B1 (en) 2004-11-17
KR20040007523A (ko) 2004-01-24
BG108311A (bg) 2004-12-30
EA200301166A1 (ru) 2004-04-29
EA006627B1 (ru) 2006-02-24
CN1547484A (zh) 2004-11-17
JP4101661B2 (ja) 2008-06-18
JP2004527569A (ja) 2004-09-09
DE60201988D1 (de) 2004-12-23
HU229938B1 (en) 2015-01-28
JO2401B1 (en) 2007-06-17
PE20021159A1 (es) 2002-12-20
HRP20030873A2 (en) 2005-08-31
NO20034689D0 (no) 2003-10-20
WO2002089835A2 (en) 2002-11-14
DE60201988T2 (de) 2005-12-15
CA2444116A1 (en) 2002-11-14
GEP20053466B (en) 2005-02-25
UA76463C2 (en) 2006-08-15
TWI234461B (en) 2005-06-21

Similar Documents

Publication Publication Date Title
RS83503A (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
YU21999A (sh) Farmaceutske smese i postupak za njihovo dobijanje
EP1120109A3 (en) Rapidly disintegrating and fast dissolving solid dosage form
DZ3478A1 (fr) Monohydrate cristallin, procede pour sa fabrication et son utilisation pour la fabrication d'un medicament.
HUP0101336A3 (en) Process for the preparation of perindopril and their pharmaceutically acceptable salts
MXPA03002070A (es) Proceso de anticoncepcion y forma de administracion para el mismo.
MY121669A (en) Fast-dissolving galanthamine hydrobromide tablet
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
WO2001043747A8 (fr) Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
ZA200108001B (en) Processes for making pharmaceutical oral ECB formulations and compositions.
HUP0200363A2 (en) Lhrh antagonist decapeptides, pharmaceutical compositions comprising thereof and processes for their preparation
HK1073319A1 (en) Process for the preparation of isoolefin copolymers, and the related catalyst and the application thereof
MXPA03005840A (es) Composicion farmaceutica solida termoformable, para liberacion controlada de ivabradina.
CA2433366A1 (en) Amlodipine free base
WO2001042272A3 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
CA2209868A1 (en) Pharmaceutical compositions comprising cefuroxime axetil
UY27278A1 (es) Forma de dosificación farmacéutica del mesilato de nelfinavir amorfo
HUP0204111A3 (en) Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
HUP0103090A3 (en) Vitronectin receptor antagonist oxazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
PL1499278T3 (pl) Farmaceutyczna postać użytkowa o natychmiastowym uwalnianiu zawierająca polimorficzny tibolon
CA2285852A1 (en) Pharmaceutical tablet comprising lisinopril disodium and microcrystalline cellulose
SI1250320T1 (en) Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
AU2002221139A1 (en) Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof